Creative Medical Technology Holdings, Inc. (CELZ) stock
CELZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.47−0.01 (-2.16%)
Close on Nov 18, 2026Market cap $3.07MP/E –Yield –
Creative Medical Technology gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Creative Medical Technology's gross profit for the twelve months ending Jun 30, 2026 was $2.01K, down 44.3% year over year. For fiscal 2025 it was $3.81K, down 42.3% from the year before. The highest annual figure on record is $120.00K in fiscal 2019.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.81K | -42.3% |
| FY2024 | Dec 31, 2024 | $6.60K | +22.2% |
| FY2023 | Dec 31, 2023 | $5.40K | -91.0% |
| FY2022 | Dec 31, 2022 | $60.11K | +51.0% |
| FY2021 | Dec 31, 2021 | $39.81K | -65.1% |
| FY2020 | Dec 31, 2020 | $113.90K | -5.1% |
| FY2019 | Dec 31, 2019 | $120.00K | +122.1% |
| FY2018 | Dec 31, 2018 | $54.03K | – |
| FY2017 | Dec 31, 2017 | -$3.20K | – |
| FY2016 | Dec 31, 2016 | $0 | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $0 | – |
| Q1 FY2026 | Mar 31, 2026 | $0 | -100.0% |
| Q4 FY2025 | Dec 31, 2025 | $2.01K | +11.4% |
| Q3 FY2025 | Sep 30, 2025 | $0 | – |
| Q2 FY2025 | Jun 30, 2025 | $0 | -100.0% |
| Q1 FY2025 | Mar 31, 2025 | $1.80K | – |
| Q4 FY2024 | Dec 31, 2024 | $1.80K | 0.0% |
| Q3 FY2024 | Sep 30, 2024 | $0 | -100.0% |
| Q2 FY2024 | Jun 30, 2024 | $4.80K | – |
| Q1 FY2024 | Mar 31, 2024 | $0 | – |
| Q4 FY2023 | Dec 31, 2023 | $1.80K | -86.0% |
| Q3 FY2023 | Sep 30, 2023 | $3.60K | -90.8% |
| Q2 FY2023 | Jun 30, 2023 | $0 | – |
| Q1 FY2023 | Mar 31, 2023 | $0 | -100.0% |
| Q4 FY2022 | Dec 31, 2022 | $12.90K | -54.4% |
| Q3 FY2022 | Sep 30, 2022 | $39.00K | +550.0% |
| Q2 FY2022 | Jun 30, 2022 | $0 | -100.0% |
| Q1 FY2022 | Mar 31, 2022 | $8.21K | – |
| Q4 FY2021 | Dec 31, 2021 | $28.31K | +197.9% |
| Q3 FY2021 | Sep 30, 2021 | $6.00K | -89.9% |
| Q2 FY2021 | Jun 30, 2021 | $5.50K | -67.8% |
| Q1 FY2021 | Mar 31, 2021 | $0 | -100.0% |
| Q4 FY2020 | Dec 31, 2020 | $9.50K | – |
| Q3 FY2020 | Sep 30, 2020 | $59.40K | +20.0% |
| Q2 FY2020 | Jun 30, 2020 | $17.10K | -59.7% |
| Q1 FY2020 | Mar 31, 2020 | $27.90K | -23.7% |
| Q4 FY2019 | Dec 31, 2019 | -$8.46K | -129.6% |
| Q3 FY2019 | Sep 30, 2019 | $49.50K | +209.3% |
| Q2 FY2019 | Jun 30, 2019 | $42.40K | +1766.2% |
| Q1 FY2019 | Mar 31, 2019 | $36.56K | +407.8% |
| Q4 FY2018 | Dec 31, 2018 | $28.55K | – |
| Q3 FY2018 | Sep 30, 2018 | $16.01K | – |
| Q2 FY2018 | Jun 30, 2018 | $2.27K | – |
| Q1 FY2018 | Mar 31, 2018 | $7.20K | – |
| Q4 FY2017 | Dec 31, 2017 | -$3.20K | – |
| Q3 FY2017 | Sep 30, 2017 | $0 | – |
| Q2 FY2017 | Jun 30, 2017 | $0 | – |
| Q1 FY2017 | Mar 31, 2017 | $0 | – |
See a number that looks wrong?